Thus, meta-analysis of data from >1500 PCa patient specimens shows that TMPRSS2-ERG fusion and TP53 inactivation co-occur in PCa patient samples, raising the potential for a cooperative role of these two lesions in prostate tumorigenesis and progression. The gene discussed is TP53; the disease is posterior cortical atrophy.